NASDAQ:XFOR - X4 Pharmaceuticals News Headlines

$14.78

+0.05 (+0.34 %)

(As of 07/17/2019 04:00 PM ET)

Add

Today's Range

$14.51

Now: $14.78▼

$15.00

50-Day Range

$13.77

MA: $15.09▼

$17.89

52-Week Range

$6.90

Now: $14.78▼

$29.46

Volume203 shs

Average Volume53,104 shs

Market Capitalization$183.57 million

P/E RatioN/A

Dividend YieldN/A

Beta1.89

Source:

Date	Headline
	Comparing X4 Pharmaceuticals (NASDAQ:XFOR) and Sangamo Therapeutics (NASDAQ:SGMO) www.americanbankingnews.com - July 11 at 10:06 AM
	X4 Pharmaceuticals Inc (NASDAQ:XFOR) Expected to Announce Earnings of -$0.79 Per Share www.americanbankingnews.com - July 6 at 10:23 PM
	X4 Pharmaceuticals Inc (NASDAQ:XFOR) Short Interest Down 10.3% in June www.americanbankingnews.com - June 28 at 5:10 AM
	X4 Pharmaceuticals Initiates Pivotal Phase 3 Clinical Trial of Mavorixafor for the Treatment of WHIM Syndrome finance.yahoo.com - June 26 at 3:18 PM
	X4 Pharma to fund no-cost genetic testing for rare immune deficiency disorder; shares up 3% seekingalpha.com - June 12 at 3:06 PM
	X4 Pharmaceuticals Prices $85.8 Million Public Offering of Common Stock and Class A Warrants finance.yahoo.com - May 22 at 8:37 AM
	X4 Pharmaceuticals Appoints E. Lynne Kelley, M.D. as Chief Medical Officer finance.yahoo.com - May 22 at 8:37 AM
	X4 Pharmaceuticals and The Leukemia & Lymphoma Society Announce Collaboration to Advance Development of Mavorixafor in Waldenström’s Macroglobulinemia finance.yahoo.com - May 22 at 8:37 AM